Laal S, Samanich K M, Sonnenberg M G, Zolla-Pazner S, Phadtare J M, Belisle J T
Department of Pathology, New York University Medical Center, New York 10016, USA.
Clin Diagn Lab Immunol. 1997 Jan;4(1):49-56. doi: 10.1128/cdli.4.1.49-56.1997.
The selection of antigens of Mycobacterium tuberculosis for most studies of humoral responses in tuberculosis patients has been restricted to molecules that were either immunodominant in immunized animals or amenable to biochemical purification rather than those that were reactive with the human immune system. Delineation of antigens that elicit humoral responses during the natural course of disease progression in humans has been hindered by the presence of cross-reactive antibodies to conserved regions on ubiquitous prokaryotic antigens in sera from healthy individuals and tuberculosis patients. The levels of cross-reactive antibodies in the sera were reduced by preadsorption with Escherichia coli lysates, prior to studying their reactivity against a large panel of M. tuberculosis antigens to which the human immune system may be exposed during natural infection and disease. Thus, reactivity against pools of secreted, cellular, and cell wall-associated antigens of M. tuberculosis was assessed by an enzyme-linked immunosorbent assay (ELISA). Initial results suggested that the secreted protein preparation contained antigens most frequently recognized by the humoral responses of pulmonary tuberculosis patients. The culture filtrate proteins were subsequently size fractionated by preparative polyacrylamide gel electrophoresis, characterized by reaction with murine monoclonal antibodies to known antigens of M. tuberculosis by an ELISA, and assessed for reactivity with tuberculous and nontuberculous sera. Results show that a secreted antigen of 88 kDa elicits a strong antibody response in a high percentage of patients with pulmonary tuberculosis. This and other antigens identified on the basis of their reactivity with patient sera may prove useful for developing serodiagnosis for tuberculosis.
在大多数针对结核病患者体液免疫反应的研究中,结核分枝杆菌抗原的选择局限于在免疫动物中具有免疫优势或易于进行生化纯化的分子,而非那些能与人体免疫系统发生反应的分子。在人类疾病自然进展过程中引发体液免疫反应的抗原的确定,受到健康个体和结核病患者血清中针对普遍存在的原核抗原保守区域的交叉反应性抗体的阻碍。在研究血清对一大组结核分枝杆菌抗原的反应性之前,先用大肠杆菌裂解物进行预吸附,以降低血清中交叉反应性抗体的水平,人体免疫系统在自然感染和疾病过程中可能会接触到这些抗原。因此,通过酶联免疫吸附测定(ELISA)评估了血清对结核分枝杆菌分泌抗原、细胞抗原和细胞壁相关抗原混合物的反应性。初步结果表明,分泌蛋白制剂所含的抗原最常被肺结核患者的体液免疫反应所识别。随后,通过制备性聚丙烯酰胺凝胶电泳对培养滤液蛋白进行大小分级,通过ELISA用针对结核分枝杆菌已知抗原的鼠单克隆抗体进行鉴定,并评估其与结核和非结核血清的反应性。结果显示,一种88 kDa的分泌抗原在高比例的肺结核患者中引发强烈的抗体反应。这种以及基于其与患者血清反应性鉴定出的其他抗原,可能对开发结核病血清诊断方法有用。